树突状细胞与胃癌细胞融合诱导抗肿瘤免疫反应的体外实验研究

Research on the experiment of eliciting specific antitumor immunity by fusion of dendritic cell with gastric cancer cells in vitro

目的:利用杂交瘤技术将脐血来源DCs和SGC7901胃癌细胞融合,以研究融合细胞的生物学特性及其抗肿瘤的功能。方法:利用聚乙二醇(PEG)化学融合技术将DCs和胃癌SGC7901细胞融合,SP免疫组化方法鉴定细胞表型;MTT法测定融合细胞刺激同源异体T淋巴细胞增殖效应;细胞毒性试验检测融合细胞诱导的细胞毒T淋巴细胞(CTL)对SGC7901的杀伤作用。结果:DCs和SGC7901胃癌细胞在PEG的作用下成功融合,其融合细胞即表达肿瘤标记物CEA,又表达DCs标记物HLA-DR,融合细胞刺激T淋巴细胞增殖能力显著高于DCs、DCs+SGC7901及SGC7901。融合细胞活化的CTL对胃癌细胞杀伤率为21.4%±0.0165%,明显高于DCs组(16.3%±0.0015%)、混合细胞(15.3%±0.0044%)及胃癌组(11.2%±0.0156%)。结论:脐血来源的DCs在PEG作用下能成功与胃癌细胞融合,且融合细胞可有效诱导T淋巴细胞产生强大抗肿瘤免疫作用。

Objective： By hybrid technology, to study the biological characteristics and antitumor function of gastric cancer-dendritic fusion cells through the fusion of dendritic cells from cord blood with gastric cancer cells SGC7901,Method： DCs from cord blood were fused with SGC7901 in the presence of 50% polyethylene glycol. The morphology and phenotype of DCs,SGC7901 and DCs/SGC7901 were respectively observed by SP immunocytechemical staining. The ability of DCs/SGC7901 which stimulated proliferation of autologous T lymphocytes was assessed by MTr, and the kill rate of cytotoxic T lymphecytes （CTL） to SGC7901 induced by FCs （fusion cells） was evaluated through cytotoxic test. Reset： DCs were successfully fused with SGC7901 in the presence of PEG, FCs expressed CEA and HLA-DR two phenotypes. Moreover, fusion cells had greater ability to stimulate proliferation ofT lymphocytes than DCs,DCs ＋ SGC7901,SGC7901, and the kill rate of FCs （21.4% ± 0.0165%） was greatty high than that of DCs （16.3% ± 0.0015%）, DCs ＋ SGC7901 （15.3% ± 0.0044%）,SGC7901 （11.2% ± 0.0156%）. Conclusion： DCs from cord blood can be successfully fused with SGC7901 in the presence of PEG, and FCs can effectively stimulate T lymphocytes to elicit antitumor immunity effect.